The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

In a recent installment of the International Society of Automation’s “Ask the Automation Pros” series, Erik Cornelsen, ...

Veteran male athletes who have spent years training at high intensity may be at greater risk of serious heart problems while ...

Veteran male athletes who have spent years training at high intensity may be at greater risk of serious heart problems while exercising, new University of Leeds research shows. The study shows that ...

Veteran male athletes who have spent years training at high intensity may be at greater risk of serious heart problems while exercising, new ...

After a week of trawling the floor at CES 2026 in Las Vegas, the Wareable team picks out the 'Best in Show' wearables from ...

Pakistan’s financial markets are changing fast, but not always in balanced ways. Technology has made investing ...

Pakistan’s financial markets are changing fast, but not always in balanced ways. Technology has made investing ...